FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biochemistry and immunology. What is considered is an isolated antibody molecule which binds an alpha chain of human granulocyte/macrophage colony stimulating factor receptor (GM-CSFRα) and inhibits GM-CSF binding to human GM-CSFRα. There are presented: a composition for GM-CSFRα inhibition or neutralisation and a composition for treating rheumatoid arthritis, asthma, chronic obstructive pulmonary disease or myeloid leukaemia, containing the antibody under the invention; the isolated nucleic acid molecule coding the antibody under the invention, a host cell and a method for preparing the antibody under the invention, as well a method for inhibiting or neutralising GM-CSFRα activity and a method of treating rheumatoid arthritis, asthma, chronic obstructive pulmonary disease or myeloid leukaemia in a patient.
EFFECT: invention can find further application in therapy of the GM-CSFRα-mediated diseases.
41 cl, 5 tbl, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ELEMENT BOUND WITH INTERLEUKIN-4 RECEPTOR α (IL-4Rα)-173 | 2008 |
|
RU2490278C2 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
| FGF21 MIMETIC ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2774368C2 |
| HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
| METHOD FOR GM-CSFRα INHIBITION IN PATIENT | 2012 |
|
RU2639546C2 |
| ANTIBODIES TO CD70 | 2012 |
|
RU2604196C2 |
| ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2739946C2 |
| NEUTRALIZING BINDING MOLECULES DIRECTED AGAINST INFLUENZA VIRUS, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2721706C2 |
| METHODS FOR TREATING FGF21-RELATED DISORDERS | 2016 |
|
RU2752530C2 |
| ANTIBODIES AGAINST HEPATITIS B VIRUS AND THEIR USE | 2020 |
|
RU2803082C2 |
